Basic info
Industry
biotechnology research
Sectors
Biotechnology
Nasal granisetron for the treatment of CINV.
Targeted leukapheresis for the treatment of IBD.
Product Research
Novel allosteric inhibitors of Akt
Biopharma
ALM201: a very potent peptide anti-angiogenic with a novel mechanism of action.
including subtype-selective inhibitors.
Date founded
2008
Funding rounds raised
Total raised
$2.6M
from 1 investors over 1 rounds
A
Almac Discovery raised $2.6M on August 13, 2018
Investors: Innovate UK